Dr. Patrick Hwu welcomes Dr. Fred Locke, chair of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center. Dr. Locke shares his personal and professional journey into CAR T-cell therapy, shaped in part by his own father’s cancer battle. A leader in pivotal clinical trials, Dr. Locke explains how engineered T cells are transforming lymphoma treatment — offering durable, sometimes curative responses. He discusses the science behind CAR T-cell manufacturing, trial design and its growing applicatio to diseases like multiple myeloma, along with future innovations in cellular immunotherapy.
What You’ll Learn from Dr. Locke
-
How a personal family experience inspired Dr. Locke’s passion for immunotherapy
-
The story behind pivotal CAR T clinical trials (ZUMA-1 and ZUMA-7) and their FDA approvals
-
What makes CAR T therapy so effective in blood cancers — and the challenges with solid tumors
-
Innovative approaches on the horizon: donor-derived CAR Ts, TIL therapy, and engineered TCR therapies
-
Why diet, exercise, and prehabilitation may improve immune cell therapy outcomes
-
How Moffitt is scaling CAR T for outpatient treatment and community hospital access
Access more show notes, links and transcript here: https://www.moffitt.org/about-moffitt/podcasts/immunoverse/future-of-cellular-treatments/
